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ABSTRACT
HLA matching between the donor and recipient improves the success of unrelated hematopoietic stem cell
transplantation (HSCT). Because many patients in need of an unrelated transplant have only donors with
mismatch, information is needed to evaluate the limits of HLA mismatching. We examined the association
of survival, acute graft-versus-host disease (aGVHD) and relapse with HLA-A, -B, -C, -DRB, -DQB1, and
-DPB1 mismatching in 334 patients coming from 12 French transplant centers and who received a non-T
cell-depleted bone marrow graft from an unrelated donor. All patients were prepared with the use of
myeloablative conditioning regimens. Our analyses demonstrate negative effects of HLA mismatching for
either HLA-A, -B, -C, -DRB1, or -DQB1 loci on survival. Multivariate Cox analyses showed that a single
mismatch was associated with a significant decrement in survival (P  .046, hazard ratio [HR]  1.41,
confidence interval [CI] 95% 1.1-1.98). The presence of multiple mismatches was worse for survival (P  .003,
HR 1.91, CI 95% 1.26-2.91) and severe aGVHD (grade III-IV) (P .002, HR 2.51, CI95% 1.41-4.46). The
cumulative incidences of aGVHD and relapse in those HLA-A, -B, -C, -DRB1, and -DQB1 identical pairs with
2, 1, or 0 DPB1 incompatibilities were 63%, 50%, and 51%, and 12%, 27%, and 20%, respectively, but these
differences were not statistically significant. Similar differences of aGVHD and relapse, but not statistically
significant, were observed in those HLA-A, -B, -C, -DRB1, and -DQB1 identical pairs with DPB1 disparities
classified into permissive or nonpermissive mismatches according to Zino’s classification based on a hierarchy
of the immunogenicity of the HLA-DP molecules. “Missing killer cell immunoglobulin-like receptor (KIR)
ligand” evaluated on the presence of HLA-C1, -C2, and Bw4 groups in the recipients was not associated with
aGVHD, survival, and relapse in this cohort of non-T cell-depleted HSCT.
© 2007 American Society for Blood and Marrow Transplantation
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P. Loiseau et al.966NTRODUCTION
Graft-versus-host disease (GVHD), graft rejec-
ion, and delayed immune recovery are the major
bstacles to successful allogeneic hematopoietic stem
ell transplantation (HSCT), and are more severe and
requent following HSCT with an unrelated donor
UD) compared to HLA identical sibling transplant.
ecause identical donors are available to only about
0% of the patients, the identiﬁcation of a suitable
nrelated donor by a better and precise HLA match-
ng of donor and recipient is necessary.
The level of HLA matching for an optimal HSCT
utcome is still a debatable question. The debate con-
erns the number of authorized HLA mismatches. Some
ata have suggested that adverse effect on survival is
bserved with a single HLA-A, -B, -C, or -DRB1 mis-
atch [1,2]. Controversies remain as to whether mis-
atches at some loci have more profound clinical con-
equences than those at other loci. Every HLA locus has
een reported to inﬂuence the outcome of unrelated
onor HSCT [1-4]. However, the respective association
f some of these HLA loci seems to vary with respect to
ifferent populations: for instance, HLA-A mismatches
eem to be more detrimental in the Japanese population
han in Caucasians [3,5].
Currently, in most transplant centers, HLA-DPB1
nd HLA-DRB3/4/5 are not taken into account for
he choice of unrelated donors. Only 1 study had
ooked at the association of DRB3 with HSCT out-
ome and did not observe any association. But its
imited size made it difﬁcult to reach deﬁnitive con-
lusions [6]. For HLA-DPB1, there is now growing
ody of a bulk of evidence supporting a role of its
atching status in the outcome of unrelated HSCT
7-12]. However, because of the relative lack of link-
ge disequilibrium between HLA-DP loci and the rest
f the extended MHC haplotype, it is difﬁcult to ﬁnd
n unrelated donor matched for HLA-DPB1 in addi-
ion to the other “classic” HLA loci. Therefore, an
lgorithm for permissiveness of HLA-DPB1 in
SCT transplantation was proposed [13]. Addition-
lly, it remains uncertain whether mismatches that can
nly be detected using high-resolution typing are
ore predictive of clinical success than those mis-
atches that can be detected at low-resolution typing.
In this report, we reviewed the collaborative ex-
erience of 9 French HLA laboratories and 12 trans-
lant centers. Three hundred thirty-four patients who
eceived an unmanipulated bone marrow graft from
n unrelated donor between 1993 and 2003 were
yped at high resolution for HLA-A, -B, -C, -DRB1,
DRB3/4/5, -DQB1, and -DPB1 loci. The respective
ssociation of each HLA loci, the effects of HLA
ismatching, and the association of the number of
ismatches between donor and recipient with
VHD, relapse, and overall survival (OS) were stud-ed. The implications of these ﬁndings for donor se-
ection are discussed.
ATERIALS AND METHODS
atient, Donor, and Transplant Characteristics
Three hundred thirty-four patients who received
n unmanipulated bone marrow graft from an unre-
ated donor between 1993 and 2003 (56% between
999 and 2002) were included in this analysis. The
rafts were performed in 12 French transplant centers
or myelogenous leukemia (acute myelogenous leuke-
ia [AML], chronic myeloid leukemia [CML] and
yelodysplastic syndrome [MDS]), for lymphoid dis-
ases (acute lymphoid leukemia [ALL] and non-
odgkin lymphoma [NHL]), for aplastic anemia or
or inborn errors. The main patient, disease, and
ransplant characteristics are described in Table 1.
The minimal clinical information collected for
ach case were acute GVHD (aGVHD) (date of onset
nd grade), relapse, date of last visit, and alive/dead
tatus. All patients were prepared for transplantation
able 1. Patient, Disease, and Transplant Characteristics
Characteristics n  334
ecipient
Age, median (range) 23.34 (1-56)
Female 143 (43%)
Children (<17 years) 85 (25%)
nderlying diagnosis
Chronic myelogenous leukemia 67 (20%)
Acute leukemia 175 (52%)
AML 80 (46%)
ALL 91 (52%)
Others 4 (2%)
Myelodysplastic syndrome 31 (9.3%)
Non-Hodgkin lymphoma 13 (3.9%)
Aplastic anemia 35 (10.5%)
Inborn errors 4 (1.2%)
Other diagnoses 9 (2.7%)
onor
Female 154 (46%)
Sex match (donor/recipient) 193 (58%)
Female to female 78 (24%)
Female to male 76 (23%)
Male to male 115 (34%)
Male to female 65 (19%)
MV matching
Donor pos. recipient neg. 70/304 (23%)
Donor pos. recipient pos. 48/304 (16%)
Donor neg. recipient neg 124/304 (41%)
Donor neg. recipient pos. 62/304 (20%)
ransplant
Source of stem cells Unmanipulated bone
marrow (100%)
onditioning regimen myeloablative(100%)
TBI 235/277 (85%)
ML indicates acute myelogenous leukemia; ALL, acute lympho-
blastic leukemia; CMV, cytomegalovirus; TBI, total body irra-
diation.
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HLA Association with Bone Marrow Transplantation 967ith the use of myeloablative conditioning regimens.
he source of grafted cells for all patients was bone
arrow without T cell depletion.
linical Endpoint Definitions
aGVHD. Grading the severity of aGVHD was
erformed according to published criteria [14]. All
atients were considered evaluable for aGVHD at
ay 1 after transplantation. The overall incidence of
GVHD grade II-IV in this cohort was 53.9% (180/
34). This was reported to be grade II in 101 cases
30.2%), grade III in 37 cases (11.1%), and grade IV in
2 cases (12.6%). The incidence of severe aGVHD
grade III-IV) was 23.7% (79 cases).
Survival. At the time of the study, 135 patients had
urvived (40%) and 199 were dead.
Relapse. Fifty-ﬁve of 289 (19%) cases suffering
rom malignant disease have relapsed at the time of
he study.
The outcome of the 334 transplants is summarized
n Table 2.
LA Polymorphism Analysis
Peripheral blood leukocytes from patients and do-
ors were used as source of DNA, which was extracted
sing the salting-out technique.
HLA medium resolution typing for HLA-A, -B,
C, -DRB1, -DQB1, and -DPB1 was performed using
he polymerase chain reaction (PCR)-sequence spe-
iﬁc oligonucleotide (SSO) reverse dot blot kits
InnoLipa HLA-A, -B, -C, -DRB, -DQB, and -DPB
its; Innogenetics, Zwijndrecht, Belgium, or Life-
odes kits, CT United States) or using the PCR-
equence speciﬁc primer (SSP) kits (homemade kits or
neLambda, Inc., Canoga Park, CA, or Genovision,
est Chester, PA, or Dynal, Invitrogen, Cergy-Pon-
oise, France). In some cases, HLA-A and -B were
yped using the standard microlymphocytotoxicity se-
ologic method with monoclonal antibodies (mAb)
One Lambda, Inc., Canoga Park, CA), which deﬁned
4 HLA-A and 48 HLA-B antigens.
Each sample was typed at the allelic level using the
CR-SSP ampliﬁcations (OneLambda, Inc. or Geno-
ision, or Dynal, Invitrogen) or by monoallelic Se-
able 2. Main Clinical HSCT Endpoints of the 334 Transplants
Outcome Number
ollow-up* 135 (41%)
eath 199 (59%)
cute GVHD (grade II-IV) 180 (53.9%)
evere acute GVHD (grade III-IV) 79 (23.7%)
elapse 55 (19%)
VHD indicates graft-versus-host disease.
For patients alive at the time of the study.uence Based Typing method using homemade
its [15].
For the analysis of aGVHD, an HLA allele mis-
atch among the donor-recipient pair was scored
hen the recipient’s alleles were not shared by the
onor (GVHD vector). For the analysis of survival,
he mismatch was deﬁned as that of either the GVHD
ector or the rejection vector (donor’s alleles not
hared by the recipient).
tatistical Analysis
Differences in categoric variables between 2
roups were evaluated by chi-square analysis. Contin-
ous variables were compared between groups by
-tailed unpaired t-tests. Clinical variables were: re-
ipient’s age, recipient and donor sex, diagnosis, re-
ipient and donor CMVserology. The univariate
aplan-Meier analysis was used to describe risk fac-
ors of death. Univariate analysis using competing risk
ethod as described by Fine and Gray [16] was used
or assessment of prognosis factors of GVHD and
elapse with death (without relapse for relapse analy-
is) as a competing event. Cox proportional hazards
odel analyses were used to identify independent risk
actors for death. The proportionality assumption for
ach of the variables contained in the ﬁnal model was
hecked by testing the dependency of their relative
isk estimate over time. If this assumption was not
hecked for a variables, this 1 was used as a stratiﬁca-
ion variable, a different baseline survival function was
ompute for each stratum. Classical available pregraft
isk factors were included in the multifactorial analy-
is, that is, CMV seronegative donor/CMV seroposi-
ive recipient, female donor/male recipient, and age of
ecipient (17 years).
Competing risk regression as described by Fine
nd Gray (16) was used to identify independent risk
actors for aGVHD. All tests were 2 sided, and the
ype 1 error rate was ﬁxed at 0.05. The Statistical
ackage for Social Scientists (SPSS 13) was used for
ata management and analysis by Kaplan Meier and
ox Methods. The R Package “cmprsk” developed by
ray was used for competing risk analysis.
ean Median Minimum Maximum
onths 35.6 1 144
onths 3.6 <1 71
ays 17 2 100
ays 16 2 82
onths 8.8 1 45.6M
41.6 m
7.5 m
22.5 d
22.5 d
12.3 m
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P. Loiseau et al.968ESULTS
ype and Number of Mismatches at HLA-A, -B,
C, -DRB1, -DRB3/4/5, -DQB1, and -DPB1 Present
n the 334 Donor/Recipient Pairs
The number and the type of HLA mismatches
etected among the 334 donor-recipient pairs are re-
orted in Table 3.
As illustrated, 7.8% of the donor-recipient pairs
ere mismatched at the HLA-A, 10.5% at the
LA-B, 27% at the HLA-C, 3.3% at the HLA-
RB1, 7% at the DQB1, and 86% at the HLA-DPB1
ocus. HLA-C and -DPB1 loci were those with the
ost frequent mismatches. This results from the
ode of selection of the donors: the compatibility
etween donor and recipient was ﬁrst required for
LA-DRB1 and -DQB1, and second for HLA-A and
B. HLA-C compatibility was taken into account only
ince 1997. HLA-DPB1 was not considered except if
everal donors were available.
Eighty-ﬁve percent (88 of 103) of HLA-C, 89%
333 of 373) of DPB1, and 37% (10 of 27) of HLA-A
ismatches were detectable by low-resolution typing
nd corresponded to differences in groups of alleles.
e called these mismatches as “antigen” mismatches.
t the opposite, 92% (34 of 37) of HLA-B and all
able 3. Number and Types of HLA Mismatches Observed by Locus in
HLA Locus
Total of Mismatched
Pairs (n  334) (%)
Total of Mismatched
Alleles at This Locus
(n  668) (%)
26 (7.8) 27 (4)
35 (10.5) 37 (5.5)
91 (27) 103 (15.4)
RB1 11 (3.3) 11 (1.6)
RB3/4/5* 29 (9) 39 (5.8)
QB1 24 (7) 26 (3.9)
PB1 287 (86) 373 (55.8)
Number of typed pairs for DRB3/4/5, n  312.Figure 1. Effect of number of HLA-A, -B, -C, -DRB1,LA-DRB1 mismatches were allelic mismatches only
etectable by high-resolution typing.
The allelic mismatches observed at HLA-A, -B,
DRB, and -DQB1 loci concerned few groups of al-
eles: mainly HLA-A*02 *03 and *30 for HLA-A locus,
LA-B*44 and *35 for HLA-B locus, HLA-DRB1*11
nd DRB3 for HLA-DRB loci, and HLA-DQB1*06
nd *03 for DQB1 locus.
Only 27 donor-recipient pairs (8.1%) were
atched at high resolution for the HLA-A, -B, -C,
RB1, -DRB3/4/5, -DQB1, and -DPB1 loci, and
8.4% for HLA-A,-B,-C,-DRB1, and -DQB1.
ssociation of Number of Mismatches Detected at
igh Resolution with Transplant-Related
utcome
In univariate analysis using death as a competitive
isk, the number of HLA mismatches at HLA-A, -B,
C, -DRB1, or -DQB1 was associated with the risk of
evere aGVHD (grade III-IV) (Figure 1). As illus-
rated in Figure 1, the donor-recipient pairs with 0 or
mismatch had the same risk of severe aGVHD (P 
5), which was lower than pairs with 1 mismatch
respectively P  .004 and .05). The multifactorial
nalysis conﬁrmed that the grafts with 1 mismatch
nrelated HSCT Donor-Recipient Pairs
Antigenic” Mismatches
ectable at Low Resolution)
(n  668) (%)
Allelic Mismatches
(Detectable at High Resolution)
(n  668) (%)
10 (1.5) 17 (2.5)
3 (0.4) 34 (5.1)
88 (13.2) 15 (2.2)
0 (0) 11 (1.6)
21 (3.1) 18 (2.7)
10 (1.5) 16 (2.4)
333 (49.8) 40 (5.9)334 U
“
(Detor -DQB1 mismatches on grade III-IV aGVHD.
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HLA Association with Bone Marrow Transplantation 969ad a higher risk of severe aGVHD (P  .002, hazard
atio [HR] 2.51, conﬁdence interval [CI] 95% 1.41-
.46).
Considering the OS, the association of the num-
er of mismatches appeared to be more prominent.
he association on survival appeared with the ﬁrst
ismatch and increased with the number of mis-
atches: In univariate analysis, the cumulative survival
t 3 years was 45% for donor-recipient pairs with 0
ismatch at HLA-A, -B, -C, -DRB1, and -DQB1
ompared to 31% for pairs with 1 mismatch (P  .03)
nd to 23% for pairs with 1 mismatch (P  .002)
Figure 2).
A multifactorial analysis conﬁrmed that 1 mismatch
t HLA-A, -B, -C, -DRB1, or -DQB1, and that 1
ismatch were signiﬁcantly associated with a worse sur-
ival than the absence of mismatch (P  .046, HR 
.41, CI 95% 1.1-1.98, and P  .003, HR  1.91, CI
5% 1.26-2.91, respectively). Recipient age over 17 years
P  .006, HR  1.68, CI 95% 1.16-2.43) was also
ssociated with a poorer survival.
In the 289 patients grafted for malignant diseases,
he number of mismatches between donors and recip-
ents did not show any association with relapse at 3
ears (0 mismatch: 21% and 1 or 1 mismatches:
2%).
ssociation of Mismatches at Individual HLA Loci
ith Transplant-Related Outcome
We studied the association of mismatches at indi-
idual HLA loci with the moderate to severe aGVHD
grade II-IV), with the severe aGVHD (grade III-IV)
nd with the OS. To avoid the impact of mismatches
t the other loci, we considered only the donor-recip-
ent pairs matched for these other loci. For example,
nly the pairs matched for HLA-B, -C, -DRB1, andFigure 2. Effect of number of HLA-A, -B, -C, -DRBDQB1 were analyzed when the HLA-A mismatching
ssociation was evaluated.
In univariate analysis using death as competitive
isk, an association was observed between HLA-B
ismatches and severe aGVHD (46% of cumulative
ncidence in case of a mismatch versus 20% in case of
ero mismatch, P  .01) (Table 4). The small number
f mismatched pairs for HLA-A, -DRB1, or -DRB3/
/5 with other loci matched (7, 4, and 6 pair, respec-
ively) rendered the analysis for these loci underpow-
red (Table 4).
In Cox multivariate analysis, mismatches at
LA-B and -C loci were associated with a signiﬁ-
antly increased risk of grade III-IV aGVHD (P 
006, HR  2.39, CI 95% 1.29-4.45, and P  .04,
R  1.68, CI 95% 1.02-2.76, respectively).
The other outcome variable analyzed was OS. In
nivariate analysis, HLA-B and -C mismatches were
ssociated with a lower OS (P  .04 and P  .03,
espectively) (Figures 3 and 4). A Cox multivariate
nalysis studying the HLA-A, -B, -C, -DRB1, and
DQB1 loci individually and performed on the whole
eries of 334 grafts, conﬁrmed the association of
LA-B and -C mismatches with a decreased OS (P 
05, HR  1.57, CI 95% 1.01-2.46, and P  .003,
R  1.65, CI 95% 1.19-2.29, respectively).
ssociation of HLA-DPB1 Mismatches with
GVHD, Survival, and Relapse
In those HLA-A, -B, -C, -DRB1, and -DQB1
dentical pair with 2 DPB1 incompatibilities (46 pair),
e observed at day 100 an incidence of 63% of grade
I-IV aGVHD and of 51% in those with zero or 1
ncompatibility (138 pair), but this difference was not
tatistically signiﬁcant (P  .11) .No association with1, or -DQB1 mismatches on overall survival.
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P. Loiseau et al.970urvival at 3 years was observed (46%, 45%, and 42%,
espectively, in case of 0, 1, or 2 DPB1 mismatches).
The incidence of disease relapse was 20% in those
LA-A, -B, -C, -DRB1, and -DQB1 identical pair
ith 0, 27% with 1, and 12% with 2 DPB1 incom-
atibilities, but the differences between the incidences
ere not statistically signiﬁcant.
Zino et al. [13] classiﬁed the HLA-DPB1 mis-
atches into permissive and nonpermissive mis-
atches, based on a hierarchy of the immunogenicity
f the HLA-DP molecules.
Indeed, the HLA-DPB1 alleles were classiﬁed into
groups with high (group 1: DPB1*0901;*1001;
1701), intermediate (group 2: DPB1*0301; *1401;
able 4. Association of HLA Mismatching at Individual Loci with Tra
HLA Locus
Number of Mismatched
Pairs in GVHD
Direction
P
G
Ac
LA-A compatibility in B, C, DR,
DQB1 matched pairs (n  205) 7
LA-B compatibility in A, C, DR,
DQB1 matched pairs (n  208) 13
LA-C compatibility in A, B, DR,
DQB1 matched pairs (n  254) 54
LA-DRB1 compatibility in A, B,
C, DQB1 matched pairs
(n  199) 4
LA-DQB1 compatibility in A, B,
C, DRB1 matched pairs
(n  208) 12
LA-DRB3/4/5 compatibility in
A, B, C, DRB1, DQB1 matched
pairs (n  195) 5
LA-DPB1 compatibility in A, B,
C, DRB1, DQB1 matched pairs
(n  194) 141
P indicates analysis underpowered because of small number of anFigure 3. Effect of HLA-B mismatches on overall survival on 24501), or low (group 3: all other DPB1 alleles) im-
unogenicity. An HLA-DPB1 mismatch was consid-
red as permissive when the 2 mismatched alleles
elonged to the same immunogenicity group. Instead,
nonpermissive HLA-DPB1 disparity in host-versus-
raft (HVG) direction was assigned when the donor’s
llele belonged to a higher immunogenicity group as
ompared to the patient’s allele. Vice versa, an HLA-
PB1 mismatch was deﬁned as nonpermissive in
VH direction when the patient’s allele belonged to
higher immunogenicity group compared to the
onor’s allele.
In the 194 HLA-A, -B, -C, -DRB1, and -DQB1
dentical pairs, 29 had nonpermissive HLA-DPB1
Related Outcome (Univariate Analysis)
for
-IV
HD
P Value for
Grade III-IV
Acute GVHD
Number of Mismatched
Pairs in
GVH and HGV
Direction Overall Survival
UP 10 NS
.01 13 .04 (Figure 3)
NS 59 .03 (Figure 4)
17 (HLA-DRB1 and
DQB1 matching in A,
UP B, C matched pairs,
n212)
NS
NS
UP 6 UP
NS 165 NS
pairs (10); NS, not signiﬁcant; GVHD, graft-versus-host disease.nsplant-
Value
rade II
ute GV
UP
NS
NS
UP
NS
UP
NS08 grafts identical for HLA-A, -C, -DRB1, or -DQB1.
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HLA Association with Bone Marrow Transplantation 971ismatches in the HVG direction and 36 in the GVH
irection.
The incidence of grade II to IV aGVHD in those
airs who had nonpermissive HLA-DPB1 mismatches
as 67% and 50% in pairs with 0 or permissive HLA-
PB1 mismatches, but this difference was not statis-
ically signiﬁcant. The same tendency, without statis-
ical signiﬁcance, was observed for grade III to IV
GVHD (28% versus 19%).
A difference in the probability of relapse was ob-
erved between the pairs with nonpermissive (4%) and
hose with 0 or permissive HLA-DPB1 mismatches
24%), but the difference was not statistically signiﬁ-
ant.
Considering the OS, the pairs with nonpermissive
ismatches in HVG and/or GVH direction had a
urvival at 3 years (45%) similar to those with a per-
issive mismatch (45%). When considering only
rafts for malignant diseases, the same result was ob-
erved (survival at 3 years 43% in nonpermissive and
ermissive pairs).
ssociation of High- and Low-Resolution
ismatches on Transplant-Related Outcomes
Table 3 reports the number of grafts with high- or
ow-resolution mismatches at each locus.
As the number of high- or low-resolution mis-
atches at each locus was small, we studied the asso-
iation of high- or low-resolution mismatches after
egrouping the high- and low-resolution mismatches
t all loci. Considering only grafts with a single mis-
atch at 1 of the 5 loci HLA-A, -B, -C, -DRB1, or
DQB1 (whatever is the locus), low-resolution mis-
atches did not appear to be at higher risk than
igh-resolution mismatches of aGVHD grade II-IV
Figure 4. Effect of of HLA-C mismatches on overall surv52% versus 49 % at 90 days), of aGVHD grade 1II-IV (23% versus 23%), and of the OS (at 3 years
5% versus 27%).
o Association of “Missing KIR Ligand” on
GVHD, Survival, and Relapse in this Cohort of
on-T Cell-Depleted HSCT
High-resolution typing of recipient HLA-B and
LA-C alleles was used to segregate patients into the
ollowing KIR ligand groups: HLA-C1 alleles (N80)
ecognized by KIR 2DL2 and 2DL3; HLA-C2 alleles
K80) recognized by KIR 2DL1; and HLA-Bw4 al-
eles (amino acids 80-83, IALR or TALR or TLLR)
ecognized by KIR3DL1.
Several authors showed that most of Caucasoid
ndividuals (about 95%) have a full complement of
nhibitory KIR for HLA-C1, -C2, and Bw4 ligands
17-19]. Patient homozygosity for HLA-C1 group im-
lies lack of ligand for donor inhibitory KIR2DL1,
atient homozygosity for HLA-C2 implies lack of
igand for donor inhibitory KIR2DL2 or 2DL3, and
atient homozygosity for HLA-Bw6 implies lack of
igand for donor inhibitory KIR3DL1.
We looked for an association of “missing KIR
igand” (absence of ligand in the recipient for the
nhibitory KIR of the donor) with aGVHD, relapse,
nd survival.
No association of missing KIR ligand (taken indi-
idually or together) was detected with grade II-IV
GVHD or with survival in those pairs who were
LA-A, -B, -C, -DRB1, and DQB1 identical or when
he patient was grafted for malignant diseases. More-
ver, considering the whole cohort of patients grafted
or malignant diseases, missing KIR ligand was not
ssociated with relapse (C1C1 pairs 24%, C2C2 pairs
0% versus 21% for C1C2 pairs, and Bw6/Bw6 pairs
254 grafts identical for HLA-A, -B, -DRB1, or -DQB1.9% versus 27% for Bw6/Bw4 or Bw4/Bw4 pairs).
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P. Loiseau et al.972ISCUSSION
We have assessed the association of high-resolu-
ion HLA matching with transplant outcome in a
rench multicentric cohort of 334 myeloablative
on-T cell-depleted unrelated donor bone marrow
ransplantation.
Our analyses demonstrated strong negative effects
f HLA mismatching for either HLA-A, -B, -C,
DRB1, or -DQB1 loci on survival. Single mismatch
as associated with signiﬁcant decrement in survival,
lthough it did not increase the risk of aGVHD. The
resence of multiple mismatches was worse for sur-
ival and severe aGVHD (grade III-IV). These results
onﬁrm previous studies showing the association of
umber of HLA mismatches with survival and
GVHD [1,2].
Because many patients in need of an unrelated
ransplant have only donors with mismatch, we sought
o determine whether mismatches at certain locus
ere more detrimental.
Previous studies gave conﬂicting results concern-
ng the respective impact of each locus on aGVHD or
urvival. A large study of 1874 donor-recipient pairs
rom the National Marrow Donor Program (NMDP)
howed that mismatches at HLA-A, -B, -C, and
DRB1 had similar adverse effects on mortality at the
pposite to DQB1 and DPB1 mismatches [1]. On the
ther hand, reports through the Japan Marrow Donor
rogram (JMDP) did not observe any effect of mis-
atching of HLA-C and HLA class II (DRB1 and/or
QB1) on transplant outcome [3,5]. In the present
tudy, the results showed that mismatches at HLA-B
nd HLA-C locus should be avoided in order to im-
rove survival. There was no confounding effect of the
ther HLA mismatches in our study as the effect at
HLA locus was evaluated only in the donor-recipi-
nt pairs matched at the other HLA loci. Because of
he small number of mismatched pairs for HLA-A,
DRB1, or -DRB3/4/5 with other loci matched in this
ohort (7, 4, and 6 pairs, respectively), it was impos-
ible to give a conclusion on the effect of mismatching
t these loci on transplant outcome. However, to draw
eﬁnitive conclusions as to whether mismatching at
ny individual locus was associated with a distinctively
ncreased risk of mortality, studies on large cohorts of
ull matched and single mismatched pairs are neces-
ary.
These results raise the question of the immuno-
enic characteristics of the mismatches. Mismatches
ith substitutions at position 116 of HLA class I
HLA-A, -B, and -C) heavy chain were suggested to
ncrease the risk for aGVHD and transplant-related
ortality (TRM) [20]. Moreover, permissive and non-
ermissive allelic mismatches at individual locus have
een already described (A*0201/0205 as permissive
nd A*0201/0206 or B*4402/4403 as nonpermissive tismatches) [21] suggesting that it is the characteris-
ics of the mismatch at a locus that have an impact on
ransplant outcome. The knowledge of the innocuous-
ess of mismatches classiﬁed as permissive should al-
ow assignment of donors mismatched for such alleles
ithout further searches for a full match.
There is no consensus on the way to classify mis-
atches as permissive and nonpermissive. Retrospec-
ive clinical studies of the association of HLA dispar-
ties with allogeneic HSCT outcome are only effective
f performed on large numbers of transplant popula-
ions who have been characterized for HLA at high
esolution, and for whom clinical data are available.
he transplant cohort of the International Histocom-
atibility Working Group (IHWG) with 4000 pair
s at the present time the unique 1 available.
It was reported that high-resolution mismatches at
LA-A, -B, -C, and -DRB1 adversely affect outcome,
ut less so than low-resolution mismatches [1]. We
nd others [2-5] conﬁrmed the adverse effect of high-
esolution mismatches at HLA-A, -B, -C, and -DRB1,
ut we did not ﬁnd that low-resolution mismatches
ad a worse effect on HSCT outcome. This could
esult from the small number of pairs with low-reso-
ution mismatches tested here, which rendered the
nalysis underpowered. It can also be hypothesized
hat T cell repertoire (TCR) should not be able to
ecognize extensively mismatched major histocompat-
bility complex (MHC) molecules, and consequently,
o elicit an adverse immune response.
High-resolution typing for A, -B, -C, -DRB1, and
DQB1 is the common gold standard for the selection
f an UD, while HLA-DPB1 and DRB3/4/5 are not
onsidered in most transplant centers.
HLA-DPB1 effect has been analyzed in a large
umber of studies. A consensus seems to emerge as-
ociating HLA-DPB1 disparities with aGVHD [7-10]
nd with reduced risk of relapse in patients treated for
alignant diseases [9,11]. Moreover, DPB1 mis-
atches were shown to increase graft rejection after
SCT for thalassemia [12]. In this paper, we observed
n the pairs with DPB1 mismatches a higher rate of
GVHD and a lower rate of relapse but without sta-
istical signiﬁcance. Only 25% of unrelated donor-
ecipient pairs matched for HLA-A, -B, -C, -DRB1,
nd -DQB1 are also compatible for HLA-DPB1 be-
ause of the very weak linkage of disequilibrium ex-
sting between DR/DQ loci and DP locus. Conse-
uently, 75% of unrelated-donor transplants are
erformed across the DPB1 barrier. An algorithm was
reviously proposed by Fleischhauer, which was based
n the identiﬁcation of immunogenic T-cell epitope
hared by a deﬁned subset of DPB1 molecules [13].
he algorithm proposed the determination of non-
ermissive HLA-DPB1 disparities that were found to
e associated with a signiﬁcantly increased risk of
ransplant-related mortality and of grade II-IV
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HLA Association with Bone Marrow Transplantation 973GVHD in patients transplanted for malignant dis-
ases [13]. Pairs with nonpermissive HLA-DPB1 mis-
atches showed in this cohort an increased risk of
GVHD and a reduced risk of relapse but without
tatistical signiﬁcance. Only a study on a very large
ohort could give statistically signiﬁcant results. Nev-
rtheless, according to all studies that have been per-
ormed on HLA-DPB1, HLA-DPB1 seems to have a
ole on transplant outcome: DPB1 mismatches could
xert a favorable effect by reducing relapse in trans-
lants performed for malignant disorders and HLA-
PB1 compatibility seems suitable in transplants for
onmalignant disorders. In the absence of an HLA-
PB1 matched donor, Fleischhauer’s algorithm could
e a way to reduce the immunogenicity of HLA-
PB1 mismatches, and meanwhile, to improve out-
ome of transplants performed for nonmalignant dis-
rders.
In most HLA-DR haplotypes, a second DR mol-
cule is encoded by 1 of the polymorphic DRB3,
RB4, or DRB5 loci, and may be considered as an
dditional transplantation antigen. Chalandon et al.
6] observed that OS from donors with single mis-
atches at HLA-DQB1 or DRB3 (53%) was statisti-
ally comparable to 10/10 matched donors (57%), and
uggested that mismatches at HLA-DRB3 or DQB1
ere preferable to HLA-DRB1 mismatches. But the
umber of studied cases was limited (22 cases). Our
tudy with only 6 pairs with exclusive DRB3/4 incom-
atibilities did not give conclusive results concerning
he role of theses molecules on aGVHD and survival.
t is noteworthy that the amino acid difference be-
ween DRB4*0101 and DRB4*01030101, located at
osition 135, is not located in the HLA domains
nteracting with the peptide or the TCR, and conse-
uently DRB4*0101/01030101 incompatibility may
ot induce direct alloimmune response. At the oppo-
ite, the HLA-DRB3 disparities involve several amino
cids (1 to 11 amino acids) in the peptide binding site
llowing a direct alloimmune response. Only a large
tudy including a large number of DRB3/4/5 incom-
atibilities without additional HLA incompatibilities
ould clearly answer the question of the effect of
RB3/4 incompatibilities.
Population frequency data demonstrate that
early all individuals have a complete complement of
nhibitory KIR for HLA-C1, -C2, and Bw4 ligand
17-19]. Recipient homozygosity for HLA-Bw6, -C1,
r -C2 group KIR epitopes predicts lack of ligand for
IR. We tested the association of “missing KIR li-
and” with HSCT outcome of our unrelated HLA-
dentical transplants, and in contrast to previous stud-
es [22-25], we found that “missing KIR ligand” was
ot associated with any deleterious or beneﬁcial effect
n aGVHD, relapse, or OS. Our results are in accor-
ance with recent studies showing that “missing KIR
igand” is not a predictive factor for relapse afteryeloablative HSCT from HLA-identical related and
nrelated donors [26,27].
A key element to explain the discrepancies be-
ween the KIR-ligand incompatibility studies in
SCT could be the donor T cell depletion of the
raft or the use of antithymocyte globulin (ATG)
uring conditioning or GVHD prophylaxis. All these
reatments lead to in vivo depletion of donor T cells
uring the early posttransplantation period, thus mak-
ng apparent natural killer (NK)-cell alloreactivity. In
act, all reported studies showing a beneﬁcial impact
f “missing KIR ligand” on relapse and survival are
hose studying transplants with donor T cell depletion
rom CD34 selection, CD3 T cell depletion
22,23,25] or to the use of ATG [24].
In conclusion, it appears that the number of HLA
ismatches in unrelated-donor transplants is a major
isk factor of survival regardless the mismatched loci.
he classiﬁcation of the HLA disparities as permissive
nd nonpermissive is an important goal to improve
SCT as well as organ transplantation.
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